BUSINESSJul 21 · 23:16 UTCSEMAFORTom Chivers

Fervor over top-selling drugs fuels biotech dealmaking

Biotech firms are attracting significant dealmaking and investor interest, with 37 biotech acquisitions over $1 billion this year driven by pharma companies seeking to strengthen pipelines before patent expirations. The Trump administration’s regulatory approach and profits from top-selling drugs are fueling mergers, while biotech IPOs are outperforming AI-related listings.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

Biotechtopicpharma companiesorganizationTrump administrationorganizationFinancial TimesorganizationBloombergorganizationBlockbuster drugstopicTom ChiverspersonTasneem Nashrullaperson

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

BUSINESSJul 21 · 04:00 UTC
Biotech deals surge to record as fear of missing out grips Big Pharma
BUSINESSJun 4 · 05:45 UTC
‘Buying stuff like it’s going out of fashion’: Biotech M&A on track for best year since pre-Covid
BUSINESSJun 16 · 05:00 UTC
Biotech IPO window is opening but big pharma M&A still sets the pace, top bankers tell CNBC
BUSINESSJun 22 · 08:30 UTC
STAT+: Pharma goes on a spending spree, snapping up biotechs in a hurry
BUSINESSJun 25 · 04:00 UTC
Patent cliffs aren’t the only driver of the biotech M&A boom
BUSINESSJun 8 · 12:40 UTC
Incyte strikes up to $2bn deal for blood disorder biotech